Thanks Eagle for your thoughts. What was your "feeling" as to the ROW deal? Did you get the feel that Jon may just back the science and wait for the FDA approval? What difference do you think it would make to the return on the ROW? % or $ terms? Do you have a preference? My other takeout from his comments was the fact that the capital raisings meant the company has enough funds to get the P2 trials to completion regardless of the FDA decision in March. Wise and prudent management in my opinion.
Would be great to be able to briefly roll the clock forward by 6 months.
Share Price, page-2607
-
- There are more pages in this discussion • 8,284 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.14 |
Change
1.150(5.48%) |
Mkt cap ! $2.829B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.44 | $21.50 | $13.15M | 598.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 437 | $22.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.15 | 8325 | 7 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |